GlassScriptPhysician profile
Lawrence L Herman
NPI 1609955202
$13,704.84
in general payments reported to CMS, 2019-2025
33 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,265 · 2020: $3,541 · 2021: $1,281 · 2022: $1,665 · 2023: $1,899 · 2024: $1,383 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,952.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,288.21 | 2019-2023 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,124.96 | 2019-2024 | Xifaxan, Trulance |
| Qol Medical, LLC | $2,445.99 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $1,124.22 | 2020-2025 | Linzess |
| Merck Sharp & Dohme LLC | $702.02 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Pfizer INC. | $453.76 | 2021-2025 | |
| Braintree Laboratories, INC. | $429.67 | 2020-2024 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $292.35 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $193.18 | 2022-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $171.41 | 2019-2025 | Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $170.13 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $169.50 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $168.27 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $146.17 | 2020-2025 | |
| Lilly USA, LLC | $134.47 | 2023 | Mounjaro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $133.61 | 2019-2021 | |
| Amgen INC. | $105.12 | 2019-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $102.53 | 2020-2021 | |
| Sanofi Pasteur INC. | $40.93 | 2019-2023 | |
| Amarin Pharma, INC. | $33.71 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $31.46 | 2025 | Dupixent |
| Allergan, INC. | $29.65 | 2019-2020 | |
| Hydrofera LLC | $27.52 | 2022 | |
| Celgene Corporation | $25.43 | 2021-2022 | |
| Ambu INC. | $23.92 | 2024 | |
| Genentech USA, INC. | $23.66 | 2020 | |
| Vibrant Gastro, INC. | $23.66 | 2025 | Vibrant Starter Kit |
| Alfasigma USA, INC. | $19.76 | 2020 | |
| Ethicon US, LLC | $15.86 | 2022 | |
| Medtronic, INC. | $14.52 | 2022 | |
| Daiichi Sankyo INC. | $13.72 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $12.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.